Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The prevalence of adverse reactions among individuals with three-dose COVID-19 vaccination

Wang, Yuying ; Zhang, Yujie ; Zhang, Meng ; Zhang, Xiaoyu ; Li, Haibin ; Wang, Youxin ; Wang, Wei ; Ji, Jianguang LU orcid ; Wu, Lijuan and Zheng, Deqiang LU (2023) In Journal of Infection and Public Health 16(1). p.125-132
Abstract

Background: Considering the adverse reactions to vaccination against coronavirus disease 2019 (COVID-19), some people, particularly the elderly and those with underlying medical conditions, are hesitant to be vaccinated. This study aimed to explore the prevalence of adverse reactions and provide direct evidence of vaccine safety, mainly for the elderly and people with underlying medical conditions, to receive COVID-19 vaccination. Methods: From 1st March to 30th April 2022, we conducted an online survey of people who had completed three doses of COVID-19 vaccination by convenience sampling. Adverse reaction rates and 95% confidence intervals were calculated. In addition, conditional logistic regression was used to compare the... (More)

Background: Considering the adverse reactions to vaccination against coronavirus disease 2019 (COVID-19), some people, particularly the elderly and those with underlying medical conditions, are hesitant to be vaccinated. This study aimed to explore the prevalence of adverse reactions and provide direct evidence of vaccine safety, mainly for the elderly and people with underlying medical conditions, to receive COVID-19 vaccination. Methods: From 1st March to 30th April 2022, we conducted an online survey of people who had completed three doses of COVID-19 vaccination by convenience sampling. Adverse reaction rates and 95% confidence intervals were calculated. In addition, conditional logistic regression was used to compare the differences in adverse reactions among the elderly and those with underlying medical conditions with the general population. Results: A total of 3339 individuals were included in this study, of which 2335 (69.9%) were female, with an average age of 32.1 ± 11.4 years. The prevalence of adverse reactions after the first dose of inactivated vaccine was 24.6% (23.1–26.2%), 19.2% (17.8–20.7%) for the second dose, and 19.1% (17.7–20.6%) for the booster dose; among individuals using messenger RNA vaccines, the prevalence was 42.7% (32.3–53.6%) for the first dose, 47.2% (36.5–58.1%) for the second dose, and 46.1% (35.4–57.0%) for the booster dose. Compared with the general population, the prevalence of adverse events did not differ in individuals with underlying medical conditions and those aged 60 and above. Conclusions: For individuals with underlying medical conditions and those aged 60 and above, the prevalence of adverse reactions is similar to that of the general population, which provides a scientific basis regarding vaccination safety for these populations.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adverse reactions, Booster dose, COVID-19 vaccine, SARS-CoV-2, Special populations
in
Journal of Infection and Public Health
volume
16
issue
1
pages
125 - 132
publisher
Elsevier
external identifiers
  • scopus:85143851564
  • pmid:36516647
ISSN
1876-0341
DOI
10.1016/j.jiph.2022.12.004
language
English
LU publication?
yes
additional info
Funding Information: This work was supported by grants from the Beijing Municipal Health System Special Funds of High-Level Medical Personnel Construction (grant number 2022-3-042 ) and the China Scholarship Council (grant number 202008110060 ). The founder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Publisher Copyright: © 2022
id
1d3d5a9d-11a4-413f-8d8e-2760787d190e
date added to LUP
2022-12-22 16:28:57
date last changed
2024-12-10 02:01:34
@article{1d3d5a9d-11a4-413f-8d8e-2760787d190e,
  abstract     = {{<p>Background: Considering the adverse reactions to vaccination against coronavirus disease 2019 (COVID-19), some people, particularly the elderly and those with underlying medical conditions, are hesitant to be vaccinated. This study aimed to explore the prevalence of adverse reactions and provide direct evidence of vaccine safety, mainly for the elderly and people with underlying medical conditions, to receive COVID-19 vaccination. Methods: From 1st March to 30th April 2022, we conducted an online survey of people who had completed three doses of COVID-19 vaccination by convenience sampling. Adverse reaction rates and 95% confidence intervals were calculated. In addition, conditional logistic regression was used to compare the differences in adverse reactions among the elderly and those with underlying medical conditions with the general population. Results: A total of 3339 individuals were included in this study, of which 2335 (69.9%) were female, with an average age of 32.1 ± 11.4 years. The prevalence of adverse reactions after the first dose of inactivated vaccine was 24.6% (23.1–26.2%), 19.2% (17.8–20.7%) for the second dose, and 19.1% (17.7–20.6%) for the booster dose; among individuals using messenger RNA vaccines, the prevalence was 42.7% (32.3–53.6%) for the first dose, 47.2% (36.5–58.1%) for the second dose, and 46.1% (35.4–57.0%) for the booster dose. Compared with the general population, the prevalence of adverse events did not differ in individuals with underlying medical conditions and those aged 60 and above. Conclusions: For individuals with underlying medical conditions and those aged 60 and above, the prevalence of adverse reactions is similar to that of the general population, which provides a scientific basis regarding vaccination safety for these populations.</p>}},
  author       = {{Wang, Yuying and Zhang, Yujie and Zhang, Meng and Zhang, Xiaoyu and Li, Haibin and Wang, Youxin and Wang, Wei and Ji, Jianguang and Wu, Lijuan and Zheng, Deqiang}},
  issn         = {{1876-0341}},
  keywords     = {{Adverse reactions; Booster dose; COVID-19 vaccine; SARS-CoV-2; Special populations}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{125--132}},
  publisher    = {{Elsevier}},
  series       = {{Journal of Infection and Public Health}},
  title        = {{The prevalence of adverse reactions among individuals with three-dose COVID-19 vaccination}},
  url          = {{http://dx.doi.org/10.1016/j.jiph.2022.12.004}},
  doi          = {{10.1016/j.jiph.2022.12.004}},
  volume       = {{16}},
  year         = {{2023}},
}